To include your compound in the COVID-19 Resource Center, submit it here.

MEM 1003: Phase IIa data

In a double-blind, U.S. Phase IIa trial in 183 patients, MEM 1003

Read the full 125 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE